World's Best Scientists 2026 revealed!
Award Badge
Immunology
Portugal
2026

D-Index & Metrics

Immunology

D-Index
83
Citations
22838
World Ranking
1461
National Ranking
2

Medicine

D-Index
83
Citations
22905
World Ranking
15710
National Ranking
16

Markus Maeurer publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Markus Maeurer sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 375 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Markus Maeurer D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Markus Maeurer sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 83 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in Portugal Leader Award

Overview

Markus Maeurer is affiliated with Johannes Gutenberg University of Mainz in Germany. Their research primarily focuses on Medicine, with a specialization in Infectious Diseases, Oncology, Immunology, Neurology, and Epidemiology. Their published work encompasses a variety of topics related to infectious and immune system diseases.

Key research topics covered by Markus Maeurer include:

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • Tuberculosis Research and Epidemiology
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers

Maeurer's contributions have appeared prominently in several publication venues, reflecting a focus on infectious diseases and immunology. Frequent venues include:

  • International Journal of Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Regular and Young Investigator Award Abstracts
  • Frontiers in Immunology
  • The Lancet Respiratory Medicine

Their recent papers feature studies on COVID-19 immunology, treatment strategies, and infectious disease epidemiology:

  • Single-cell landscape of immunological responses in patients with COVID-19, 2020, Nature Immunology
  • Reducing mortality from 2019-nCoV: host-directed therapies should be an option, 2020, The Lancet
  • Immunological and inflammatory profiles in mild and severe cases of COVID-19, 2020, Nature Communications
  • The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB, 2022, International Journal of Infectious Diseases
  • Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial, 2020, Signal Transduction and Targeted Therapy

Collaboration has been a significant component of their research. Frequent co-authors include:

  • Alimuddin Zumla
  • Giuseppe Ippolito
  • Chiara Agrati
  • Maria Rosaria Capobianchi
  • Joana R. Lérias

Best Publications

  • Single-cell landscape of immunological responses in patients with COVID-19.

    Ji Yuan Zhang;Xiang Ming Wang;Xudong Xing;Zhe Xu

  • Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

    Stephen D Lawn;Peter Mwaba;Peter Mwaba;Matthew Bates;Amy Piatek

  • Antigen-processing machinery breakdown and tumor growth.

    Barbara Seliger;Markus J Maeurer;Soldano Ferrone

  • Reducing mortality from 2019-nCoV: host-directed therapies should be an option.

    Alimuddin Zumla;Alimuddin Zumla;David S Hui;Esam I Azhar;Ziad A Memish

  • New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

    Alimuddin I Zumla;Alimuddin I Zumla;Stephen H Gillespie;Michael Hoelscher;Patrick P J Philips

  • Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

    Simon Tiberi;Nelita du Plessis;Gerhard Walzl;Michael J Vjecha

  • Immunological and inflammatory profiles in mild and severe cases of COVID-19.

    Jin Wen Song;Chao Zhang;Xing Fan;Fan Ping Meng

  • Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

    Markus J. Maeurer;Susanne M. Gollin;Dina Martin;William Swaney

  • Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

    Alimuddin Zumla;Alimuddin Zumla;Martin Rao;Martin Rao;Robert S Wallis;Stefan H E Kaufmann

  • Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts

    Ben J Marais;Knut Lönnroth;Stephen D Lawn;Stephen D Lawn;Giovanni Battistai Migliori

  • Drug-resistant tuberculosis: time for visionary political leadership

    Ibrahim Abubakar;Ibrahim Abubakar;Matteo Zignol;Dennis Falzon;Mario Raviglione

  • Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.

    Fanping Meng;Ruonan Xu;Siyu Wang;Zhe Xu

  • TAP off — tumors on

    Barbara Seliger;Barbara Seliger;Markus J. Maeurer;Markus J. Maeurer;Soldano Ferrone;Soldano Ferrone

  • Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

    Robert S Wallis;Markus Maeurer;Peter Mwaba;Jeremiah Chakaya

  • Tuberculosis biomarkers discovery: developments, needs, and challenges

    Robert S Wallis;Robert S Wallis;Robert S Wallis;Peter Kim;Stewart Cole;Debra Hanna

  • Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.

    Lei Shi;Hai Huang;Xuechun Lu;Xiaoyan Yan

  • Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy.

    Ralf Kiesslich;Martin Goetz;Juergen Burg;Manfred Stolte

  • Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.

    Chiara Castelli;Walter J. Storkus;Markus J. Maeurer;Dina M. Martin

  • Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities

    Ruth McNerney;Markus Maeurer;Ibrahim Abubakar;Ibrahim Abubakar;Ben Marais

  • Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies

    Alimuddin Zumla;Jeremiah Chakaya;Rosella Centis;Lia D'Ambrosio

  • Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

    Stefan H. E. Kaufmann;Christoph Lange;Martin Rao;Kithiganahalli Narayanaswamy Balaji

Frequent Co-Authors

Alimuddin Zumla
Alimuddin Zumla University College London
Giuseppe Ippolito
Giuseppe Ippolito Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Michael Hoelscher
Michael Hoelscher Ludwig-Maximilians-Universität München
Michael T. Lotze
Michael T. Lotze University of Pittsburgh
Elke Jäger
Elke Jäger Goethe University Frankfurt
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Chiara Castelli
Chiara Castelli University of Milan
Chiara Agrati
Chiara Agrati Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Ben J. Marais
Ben J. Marais University of Sydney
Jiri Bartek
Jiri Bartek Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, related healthcare fields offer diverse online degree opportunities that can complement their scientific knowledge. Nursing, in particular, provides various pathways for specialization and advancement.

Those looking to enter the nursing profession quickly might explore the easiest accelerated nursing programs to get into. These programs condense coursework for faster degree completion, ideal for those transitioning from other healthcare backgrounds.

For foundational clinical roles, the best easiest lpn programs to get into offer a streamlined route to Licensed Practical Nurse certification, emphasizing practical skills and patient care.

Professional advancement within nursing could involve pursuing a Nurse Practitioner degree. Identifying which nurse practitioner program is easiest can help students select flexible, accessible programs suitable for balancing work and study.

For those interested in mental health, online pmhnp programs online with best clinical placement offer superior clinical training opportunities and job placement support, critical for launching a career as a Psychiatric-Mental Health Nurse Practitioner.

Exploring these related degrees enhances career options and provides valuable clinical expertise relevant to the field of Immunology and healthcare at large.

Best Scientists Citing Markus Maeurer

Trending Scientists

Recently Published Articles